🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

94 results for “Novo Nordisk A/S” Clear

  1. Placebo A, NNC0487-0111, NNC0487-0111, NNC0487-0111, Placebo C tablets, NNC0487-0111, METFORMIN , NNC0487-0111, NNC0487-0111, NNC0487-0111, DAPAGLIFLOZIN , NNC0487-0111

    Novo Nordisk A/S

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  2. Placebo A, NNC0519-0130, Ozempic 0.5 mg solution for injection in pre-filled pen

    Novo Nordisk A/S

    Chronic Kidney Disease, with or without Type 2 diabetes, Obesity

    phase 2 small molecule active

    1 trial

  3. Placebo A, Semaglutide B Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen

    Novo Nordisk A/S

    type 2 diabetes

    phase 2 small molecule active

    1 trial

  4. Placebo C, Semaglutide B 3.0 mg/ml PDS290, Semaglutide B placebo PDS290 pen-injector, Cagrilintide A 10 mg/mL cartridge, NNC0174-0833 A Placebo

    Novo Nordisk A/S

    Non-alcoholic steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  5. Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen

    Novo Nordisk A/S

    SGA - small for gestational age children

    phase 2 small molecule active

    1 trial

  6. cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, semaglutide, cagrilintide, cagrilintide, cagrilintide semaglutide, cagrilintide semaglutide, semaglutide, semaglutide, semaglutide, FINERENONE , DAPAGLIFLOZIN , semaglutide, cagrilintide, ENALAPRIL , cagrilintide, cagrilintide, cagrilintide semaglutide

    Novo Nordisk A/S

    Chronic Kidney Disease, Type 2 diabetes

    phase 2 small molecule active

    1 trial

  7. cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, Placebo (zalfermin) + Placebo (semaglutide), semaglutide, Placebo (cagrilintide) + placebo (semaglutide), cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, zalfermin, cagrilintide, cagrilintide

    Novo Nordisk A/S

    alcohol-related liver disease

    phase 2 small molecule active

    1 trial

  8. etavopivat B 10041, etavopivat B 10042

    Novo Nordisk A/S

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  9. A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healthy adults

    Novo Nordisk A/S

    Cardiometabolic diseases

    phase 1 other active

    1 trial

  10. A research study Looking into blood levels of the medicine NNC0519-0130 in the body of participants with normal or reduced kidney function

    Novo Nordisk A/S

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  11. A research study comparing different ways of increasing the dose of NNC0519-0130 in participants with overweight or obesity

    Novo Nordisk A/S

    Type 2 diabetes mellitus

    phase 1 other active

    1 trial

  12. A research study investigating the effect of NNC0497-0040 in healthy participants, participants with overweight or obesity, and participants with type 1 diabetes with overweight or obesity.

    Novo Nordisk A/S

    Type I diabetes

    phase 1 other active

    1 trial

  13. A research study looking at how NNC0487-0111 affects food intake, appetite and metabolism after meals in people with obesity

    Novo Nordisk A/S

    Participants with obesity, but otherwise healthy

    phase 1 other active

    1 trial

  14. A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A

    Novo Nordisk A/S

    Haemophilia A with or without inhibitors. Proposed indication under development: prevention of bleeding and long-term prophylaxis in patients with haemophilia A, irrespective of inhibitor status or severity.

    phase 1 other active

    1 trial

  15. A research study looking at how different doses of study medicine (Inno8) works in the body of healthy men.

    Novo Nordisk A/S

    Prophylaxis and on-demand treatment respectively in patients with haemophilia A with or without FVIII inhibitors.

    phase 1 other active

    1 trial

  16. A research study looking into blood levels of the medicine NNC0487 0111 in the body and how well it is tolerated in people with reduced liver function and normal liver function

    Novo Nordisk A/S

    hepatic impairment

    phase 1 other active

    1 trial

  17. A research study looking into how cagrilintide influences food intake and appetite in people with overweight or obesity

    Novo Nordisk A/S

    Obesity

    phase 1 other active

    1 trial

  18. A research study looking into the effect of NNC05190130 on blood levels of a birth control pill and emptying of the stomach in women after menopause

    Novo Nordisk A/S

    Healthy postmenopausal females (Type 2 Diabetes)

    phase 1 other active

    1 trial

  19. A research study of a new medicine (NNC0650-0013) in healthy men

    Novo Nordisk A/S

    Weight management, Diabetes mellitus type 2; healthy subjects

    phase 1 other active

    1 trial

  20. A research study of a new medicine NNC0363-1063 in healthy participants and participants with type 1 diabetes

    Novo Nordisk A/S

    Type 1 diabetes mellitus

    phase 1 other active

    1 trial

  21. A research study of a new medicine NNC0363-1063 in participants with type 1 diabetes

    Novo Nordisk A/S

    Diabetes type 1

    phase 1 other active

    1 trial

  22. A research study of a new medicine, NNC9733-0001, in healthy participants and participants with type 2 diabetes

    Novo Nordisk A/S

    Healthy Participants and Participants with type 2 diabetes

    phase 1 other active

    1 trial

  23. A research study of how safe a new medicine called NNC0519‑0130 is and to test its effect in people living with excess body weight with or without type 2 diabetes

    Novo Nordisk A/S

    Obesity, Type 2 Diabetes with either overweight or obesity

    phase 1 other active

    1 trial

  24. A research study on the effects of NNC0537-1482 in healthy individuals when injected under the skin.

    Novo Nordisk A/S

    Heart Failure

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources